The company operates Beauty Clinics specializing in Aesthetic Skin, Body and Weight Management, Plastic Surgery, and Wellness based on modern medical principles that are approved by US FDA.
| 3M23 | 3M22 | 2022 | 2021 |
|---|
| Revenues | 514.81 | 1,647.20 | 952.14 | |
| Expenses | 426.38 | 1,390.34 | 798.85 | |
| Net Profit (Loss) | 69.06 | 205.49 | 129.26 |
| Assets | 2,740.74 | 2,590.25 | 824.69 | |
| Liabilities | 1,025.92 | 944.50 | 664.18 | |
| Shareholders' Equity | 1,714.81 | 1,645.75 | 160.50 |
| Operating | 102.48 | 407.96 | 238.56 | |
| Investing | -79.73 | -1,226.44 | -51.37 | |
| Financing | -23.60 | 1,207.02 | -120.57 |
| EPS (Baht) | 0.31 | 1.21 | 0.81 | |
| GP Margin (%) | 54.76 | 56.31 | 58.82 | |
| NP Margin (%) | 13.41 | 12.48 | 13.58 | |
| D/E Ratio (x) | 0.60 | 0.57 | 4.14 | |
| ROE (%) | 13.06 | 22.75 | 80.53 | |
| ROA (%) | 10.29 | 15.04 | 18.59 |
Vision
To be a leader on an international scale for Aesthetic, Plastic Surgery, and Wellness center through the use of medical and innovative services, aiming to be the best beauty provider in South East Asia
Key Strategic Highlights
- Strengthen further Brand Equity
- Optimize the new Surgery Centre
- Monetize the macro Health and Wellness trend
- Prioritize Innovation and Safety to ensure results
- Expand coverage of the Klinique and L.A.B.X.
As of 31 March 2023, the Company has a total of 43 branches throughout Thailand
- 37 medical clinics under 'The Klinique' brand
- 5 laser centers under 'L.A.B.X.' brand
- 1 Surgery Center
The four service departments of the company’s medical clinics and surgery center are Aesthetic Skin, Body & Weight Management, Plastic Surgery, and Wellness.
In Q1/23, the Company’s total revenue from sales and service
is THB 508.97 Million increasing by 53.4% from Q1/2022 due to
branch expansion, services expansion with targeted marketing
that led to higher customer recognition and engagement, inclusive
of the risen number of tourists after the ease of Covid-19. Moreover, with the increase in sales from the Surgery Center and the Company’s new brand, L.A.B.X., which was launched in Q2/22.
- In May 2022, the Company launched a laser center sub-brand under the name "L.A.B.X" with the main target group being adolescents to the early working age. The first L.A.B.X branch is located at Siam Square One, and we now have a total of 5 laser centers in Bangkok by the end of Q1/2023.
- In 1H/22, the Company launched the new department of plastic surgery with the opening of the Surgery Center at Siam Square
- In 2022, the Company launched two of 'The Klinique' Flagship stores at Siam Paragon and The Emporium, together with the expansion of 5 branches under the Core Brand 'The Klinique'
- On 7 November 2022, the Company began its first trading day on the MAI stock exchange
- In Q1/23, the Company opened two new 'The Klinique' branches at Central Ramintra and Thonglhor, and one new 'L.A.B.X.' branch at Central Pinklao
- Risks of Competition in the Aesthetics Business
The Company has the policy to make a difference by focusing on creating a brand that consumers can recognize, focusing on providing a full range of services with cutting-edge medical innovations from Europe and the United States, developing the capabilities of personnel to meet the needs of consumers, and increasing branches nationwide to support consumer needs and to enable consumers to access our services.
- Risks from Changes in Treatment Technology
The Company focuses on quality by continuously investing in innovative and safe medical devices approved by the US FDA, considering the best safety standard. Considering our data since 2009, the average lifespan depends on the particular medical device, but mostly the device's shelf life is around 5-12 years, and still provides effective treatment. In addition, if the Company were to proceed with the purchase of medical devices exceeding 10 MB, a feasibility study must be conducted based on the payback period for such medical investment. Our management has regularly attended training & seminars related to research in treatment technology to monitor changes in various treatment technologies to develop the treatment technology. The Company also requires annual consumer needs surveys, such as looking at marketing data, conducting customer surveys, planning marketing schemes, and developing existing services to respond to consumer needs.
- The Golden Records Award: ASIA PACIFIC Highest Achievement & Thailand Top Achiever Award for Ulthera 2014 – 2022
- Top Galderma Iconic Clinic 2017-2022
- Etc.
| as of 31/03/23 | KLINIQ | SERVICE | mai |
|---|---|---|---|
| P/E (X) | 43.90 | 50.41 | 66.21 |
| P/BV (X) | 5.48 | 3.28 | 2.85 |
| Dividend yield (%) | 1.22 | 1.48 | 1.26 |
| 31/03/23 | 30/12/22 | - | |
|---|---|---|---|
| Market Cap (MB) | 9,020.00 | 8,525.00 | N/A |
| Price (B/Share) | 41.00 | 38.75 | N/A |
| P/E (X) | 43.90 | 42.78 | N/A |
| P/BV (X) | 5.48 | 5.26 | N/A |